Revive Biotechnology, Inc. is a company focused on improving oxygen delivery to various hypoxic tissues. We have developed proprietary nanotechnology and have advanced through the proof of concept studies for ocular hypoxic conditions in an animal model. We are working through the regulatory process to achieve FDA approval for this ground breaking therapeutic for ischemic retinal conditions. In the meantime we are adapting our technology to wound care, blood oxygenation to bypass diseased pulmonary tissue as well as adjuvant for cancer treatment.
by John Conrad | Apr 12, 2021 | Monday3 | 0 comments